COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Disease Control and Prevention has updated and expanded its list of people at risk of severe COVID-19 illness, the agency said.
AHA today urged the Centers for Medicare & Medicaid Services to temporarily extend certain waivers and make others permanent beyond the COVID-19 public health emergency to allow hospitals to provide better and more cost effective care to their patients and communities.
Clinicians participating in the Quality Payment Program Merit-based Incentive Payment System in 2020 whose practice was significantly impacted by the COVID-19 public health emergency may apply for an exception to reweight the MIPS performance categories, the Centers for Medicare & Medicaid鈥
The Centers for Medicare & Medicaid Services recently confirmed that Medicare contractors will not calculate an average length of stay for long-term care hospitals for cost reporting periods that include the COVID-19 public health emergency, which took effect March 1.
The Food and Drug Administration has partnered with the Critical Path Institute and National Center for Advancing Translational Sciences to launch the CURE Drug Repurposing Collaboratory, a forum for exchanging clinical practice data to inform potential new uses for existing drugs to treat unmet鈥
Hospitalization rates for COVID-19 were nearly four times higher for black, and two times higher for Hispanic, Medicare beneficiaries than for white Medicare beneficiaries, according to data on COVID-19 cases and hospitalizations released by the Centers for Medicare & Medicaid Services.
FDA issues guidance on removed COVID-19 antibody tests; reporting potential medical device shortages
Clinical laboratories and health care providers should stop using any antibody tests on the Food and Drug Administration鈥檚 鈥渞emoved鈥 test list, evaluate prior results from the test and whether to retest the patient using an FDA-authorized test, the agency said.
CDC: Emergency department visits for life-threatening conditions declined in pandemic鈥檚 early months
A new study released by the Centers for Disease Control and Prevention shows emergency department visits dropped by 23% for heart attacks, 20% for strokes and 10% for hyperglycemic crises in first 10 weeks after the COVID-19 public health emergency declaration.
A study of the first 20,000 adults hospitalized with severe or life-threatening COVID-19 to receive convalescent plasma found the investigational therapy safe in this diverse group of patients, according to findings from the Food and Drug Administration鈥檚 Expanded Access Program for COVID-19鈥
The Centers for Disease Control and Prevention recently updated its health care facility operations guidance to reflect the current COVID-19 pandemic environment.